Valora Therapeutics is a privately held biotech, co-founded with Carolyn Bertozzi, developing multispecific antibodies and T cell engagers that break the glyco-immune checkpoint. Our proprietary AbLecTM and T-LecTM platforms combine precise tumor targeting with localized glyco-immune checkpoint disruption to generate therapeutics with superior anticancer activity without the requirement for delivering toxic payloads. Valora's discovery engine was built on a $30M Seed Round led by Avalon BioVentures.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Antibody Targeted Biologics atbtherapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering next-generation antibody therapies with AI and computational protein design Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines. Archon …

83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovery of novel immune checkpoint inhibitors for cancer immunotherapy OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered …

209 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovering and developing Nanofitins® through collaboration with worldwide pharma industry leaders Affilogic is a private biotech company specialised in discovering and developing Nanofitins® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector. These affinity proteins are potent antibody-mimetics, exhibiting a high affinity and specificity for capture, targeting and interacting with biomolecules. Each Nanofitin® is 20 times smaller than an antibody (7 kDa) and demonstrates hyper stability. Nanofitins are easily combined with each other, antibodies and other biomolecules by simple, rapid and proven methods to design an ideal targeted molecule. Affilogic has designed Nanofitins® against 60+ targets to date, …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering Patient-led Antibody Therapeutics Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease. Antibody Therapies, Immunology, and Neuro-dengeneration

83 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Combining human and machine intelligence to discover the next generation of therapeutic antibodies. LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVATM, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVATM is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles. Medical, Health, and DNA Libraries

140 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: A.I. Robotics Synthetic Biology A.I. - Machine Learning

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-PrimeTM, and novel drug candidates based on the RUBYTM bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator ́s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more …

73 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Off-the-shelf precision vaccines to prevent deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Laigo's SureTAC platform enables rapid therapy development for removal of disease-driving membrane proteins #laigobio Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today. Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow. #TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs

146 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We develop Optimer® binders to enable innovation across the life science industry. Aptamer Group develops Optimer® binders to enable innovation in the life science industry. Get our newsletter: https://aptamergroup.com/newsletter Research and Development, Assay Development, Custom development, Drug development, Custom reagents, Agriculture testing, Aptamers, Biomarker discovery, Affinity ligands, Environmental testing, Affinity chromatography ligands, ADCs / AOCs, QC reagents, Diagnostic tools, and Targeted delivery

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Clinical-stage company developing proprietary protein superglue vaccines against infectious diseases, including CMV, EBV Spun out of the University of Oxford in 2017, SpyBiotech is a clinically validated vaccine company built on proprietary protein "superglue" technology. It snaps antigens onto a vaccine scaffold in a single step, giving us a faster, more reliable way to build robust vaccines. We apply this across two complementary platforms. Our virus-like particle (VLP) platform is Phase I-validated, and our viral vector platform extends the same plug-and-play approach to more targets. Together they form a flexible engine for vaccines against established and emerging diseases. Two lead …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building tomorrow's antibody-drug conjugates (ADCs) Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering. Antibody Drug Conjugates and ADCs

60 similar entities Type: Startup Activities: biotech deeptech Technologies: SaaS

MImAbs is an innovative start-up specialized in immunotherapy. Our goal is to develop monoclonal antibodies in cancer and inflammatory diseases for third parties (academics, pharmacuetical companies, biotechnologies, etc.) Anticorps monoclonaux, Immuno-pharmacologie, Génération et bioproduction d'anticorps, and Génération d'immunoconjugués

227 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

ENABLING TECHNOLOGY FOR THERAPEUTICS TARGETING MEMBRANE PROTEINS G.CLIPS biotech created the first enabling technology to unravel the potential of drug and antibody candidates on pathology-like format membrane proteins to be used in screening efforts, characterization, structural studies, mechanism of action, pharmacological profiling and target validation. We offer a unique technology to express, stabilize, select and validate membrane proteins as targets based on proprietary G.Screen® Platform. G.Mixes® G.Select® Assay G.Lipidomics® G.Validation® Assay We provide tailor-made services to pharma, biotech and animal health companies targeting membrane proteins (GPCRS, Receptors, Transmebrane Proteins) that would like to ascertain the necessary environment and conformation stabilization …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Twinkling reagents for live-cell & in vivo protein imaging: FAST · splitFAST · CATCHFIRE fluorogens & molecular glues The Twinkle Factory supplies fluorogens for FAST & splitFAST and fluorogenic molecular glues for CATCHFIRE — bright, fully reversible, oxygen-independent reagents for live-cell and in vivo protein imaging. Our catalogue spans a full colour palette of cell-permeant and non-permeant fluorogens (tfLime, tfAmber, tfCoral, tfPoppy, tfCarmine, tfAmber-NP, tfFox-NP) that switch on the instant they bind a FAST-tagged protein — no oxygen, no maturation time — plus the match-series molecular glues (match540/550/600/715, matchDark, matchKit) that reversibly and self-reportingly dimerize proteins with CATCHFIRE. Labs use …

60 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

228 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing Tomorrow's Antibacterials Antabio is a privately held, clinical-stage biopharmaceutical company dedicated to developing novel and highly differentiated antibacterial treatments targeting drug-resistant infections caused by WHO and CDC critical priority pathogens. Guided by scientific excellence and a clear mission, Antabio’s mission is to deliver life-saving therapies that combat antimicrobial resistance (AMR) and help preserve the effectiveness of antibiotics for future generations. Antabio’s lead program, MEM-ANT3310, is a next-generation β-lactam/β-lactamase inhibitor (BL/BLI) combination currently in Phase 1 clinical development. Designed to treat severe hospital infections caused by multidrug-resistant Gram-negative bacteria, MEM-ANT3310 represents a major step forward in addressing one of the …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advanced Antibody Expertise Deeptope's expertise lies in antibody charaterisation (epitope/paratope mapping) and optimisation using high throughput methods. antibody, paratope mapping, epitope mapping, and antibody optimisation

91 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Built around safe-by-design concept, Adjuvatis is committed for innovative formulations to improve pharmaceuticals Adjuvatis, a French startup in biotechnology, develops innovative safe-by-design delivery systems to help laboratories and pharmaceutical companies in vaccine formulation as adjuvants and in drug delivery as vectors for oncology, dermatology, infections, etc. Our first technology, called i-Particles®, is based on 200 nm-diameter particles composed of poly-lactic acid only (any surfactant and solvents) for formulation of hydrophobic molecules in the particle core and surface functionalization of peptides. Our second technology, i-LipoP®, consists in i-Particles® covered by lipidic bilayers at their surface for vectorization of nucleic acids and …

100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for …

175 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We produce customised chemical proteins to help our bio-pharms partners to accelerate their projects. 🧪 X’PROCHEM is a biotech company who invented an advanced and proprietary ligation technology. We help our bio-pharma partners design and create therapeutic, vaccine and diagnostic proteins. Unlike recombinant fermentation we can produce proteins containing up to 400 amino acids, without isoforms, endotoxins, or biological contaminants. We co develop solutions with our partners to understand the real needs within the context. By working closely, we can adapt to changing needs and circumstances. protein, purification, synthesis, protein production, peptide synthesis, and life sciences

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Small molecules, life-changing power. Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package.

131 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. For more information on Iterum Therapeutics please visit www.iterumtx.com.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Glycan Mediated Therapy GlycoEra is developing biologics to selectively target the root cause of many autoimmune diseases: a specific circulating protein (autoantibody). Our approach enables us to degrade targets rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies, including an improved safety profile and the potential for earlier disease intervention – which could improve patient quality of life, limit long-term complications and lower overall healthcare costs. Our best-in-class, extracellular degrader BiNDTM platform (Biologic Natural Degrader), allows us to target and rapidly, deeply degrade any circulating protein …

208 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Altevax is developing a disruptive immunotherapy technology against cancer Altevax is a Phase 2 clinical-stage biotechnology company developing a pioneering melanin-based immunotherapy platform for cancer treatment. Its patented technology enhances antigen-specific T-cell immune responses and is compatible with a broad range of peptides, with potential to complement existing immuno-oncology approaches, including anti-PD-1 therapies. Altevax’s lead program targeting TERT in glioblastoma is currently in Phase 2 clinical development. The company collaborates with leading clinical institutions, including AP-HP, and is actively fundraising and exploring strategic partnerships to accelerate development. Cancer vaccines, immunotherapy, melanin, therapeutic vaccines, Peptidic vaccines, infectious diseases, CD8 Killer T …

219 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biotech company specializing in discovery, engineering and manufacturing of monoclonal antibodies Immune Biosolutions is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development. Anticorps, Custom antibody development, Antibody, Développement sur mesure de génération d'anticorps, IgY, Chicken, Poulet, ELISA, Therapeutic Antibodies, Recombinant Antibodies, Humanized Antibodies, …

104 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Exceptional Human Antibody Discovery Technology Trianni, Inc. is a biotech company specializing in human antibody discovery platform technology. We offer the leading in vivo platform enabling efficient discovery of fully-human monoclonal antibodies. The Trianni Mouse offers biologic drug discoverers a best-in-class solution for the isolation of therapeutic antibody candidates. Benefits over older conventional mouse immunization + humanization approaches include superior lead panels with respect to potency and diversity along with speed to the clinic and lower operating costs. We aim to make Trianni’s premium technology available to any Pharma or Biotech company engaged in antibody discovery by offering flexible licenses …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine.

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Native and functional membrane therapeutic targets for improving Drug and Vaccine Discovery To contact us : contact@calixar.com CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens. We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crossing the next frontier, to give you a fair chance to fight Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms. Inflammatory Bowel Diseases, Live Biotherapeutics, Microbiome, Immunotherapies, Immuno-oncology, and Immuno-inflammation

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The clear path to small molecule visualization & quantification Over the past decade, Immusmol specialized in the development of antibodies against low molecular weight compounds (<900 Daltons), eventually building a portfolio of unique primary antibodies and ELISA kits for research use. 50 + unique primary antibodies We develop monoclonal & polyclonal antibodies and staining procedures for the visualization of small molecules in cells & tissues. 80+ ELISAs cross-validated by LC-MS Our team develops highly sensitive ELISA kits to measure amino acids and their metabolites in biological samples. 600+ clients served worldwide We deliver our products worldwide through Fedex and developed …

114 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your key partner for breakthrough antibody discovery Mabqi specializes in the discovery and development of human therapeutic antibodies. Our core technology is based on proprietary synthetic fully human libraries including pH-sensitive variants tailored for oncology applications. The company offers end-to-end discovery solutions, from antibody discovery, affinity maturation to optimization and full characterization, ensuring tailored support and delivery of high-quality and developable antibodies to meet your needs. Moreover, based on our know-how and technologies, Mabqi is committed to the discovery of therapeutic antibodies on innovative targets with off-the-shelf antibody assets available for partnered development and licensing opportunities. Antibody Discovery, Fully Human …

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A clinical-stage cancer immunotherapy company and a pioneer in computational target discovery About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (UnigenTM) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned potential best-in-class Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived …

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Targeting calcium signaling to cure auto-immune diseases KALSIOM is a biotech company founded in April 2020 and based in Brest, France, discovering and developing first-in-class therapies to treat auto-immunes disorders (AID) involving B-cell dysfunction with a high medical need. The company is focusing on developing first-in-class monoclonal antibodies modulating calcium-signaling pathways in lymphocytes. Immunology and Therapeutic antibodies

97 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

At the forefront of the fight against antibioresistant bacteria Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human cells. Antimicrobial resistant bacteria or AMR are responsible for over 700,000 death a year in 2014 according to the WHO. This number might reach over 10,000,000 by 2050 if nothing is done, and no new class of antibiotics has been discovered in the last 30 years. Phages represent one of …

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna is pioneering allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers. The company’s platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company’s lead candidate, ZI-MA4-1, is the worlds-first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026 For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

293 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Marine-inspired molecules to fight immunological diseases. Traumatic brain injury is the #1 cause of death in people under 30. Yet no therapy today addresses the immune collapse that follows severe trauma. Olgram is a biotechnology company developing first-in-class, proprietary immunotherapies to restore immune function and improve recovery after trauma. Founded in 2019 and supported by four patents, we combine cutting-edge immunology and biotechnology to pioneer the field of post-traumatic immune restoration. Biotechnologie, immunologie, antibiorésistance, and commotions

62 similar entities Type: Startup Activities: deeptech biotech

Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells. Heidelberg Pharma uses several compounds and has built up an ADC toolbox that overcomes tumor resistance via numerous pathways and …

201 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next Generation Antibody Therapy for Reversal of Amyloidosis Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis. The Company’s lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis. Immutrin's antibody is a potential best-in-class therapy, with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils.

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vaccines for the future Based on innovative, patented technology, AIOVA aims to develop and market innovative vaccines, with high added value, to its pharmaceutical industrial clients. AIOVA is positioned in the fight against emerging or re-emerging and deadly pandemics in humans and animals, in a OneHealth approach, and in particular influenza (human and avian flu), AIDS-type diseases, and, very recently, diseases caused by coronaviruses such as SARS-CoV-2, responsible for the current COVID-19 pandemic. The vaccines are designed from a patented DNA platform and have the properties of activating, in the vaccinated host, not only the production of antibodies - which …

60 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

A pioneer in the activation of the complement system to treat cancer and autoimmune disease. Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCETM) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

390 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Designing functional antibodies for the most challenging targets. Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. Machine Learning, Antibodies, and Drug discovery

149 similar entities Type: SMB Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Generative A.I. Synthetic Biology

Breaking Biology Free Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, including binders (nanobodies, bispecific antibodies), toxic proteins, and phage proteins.

165 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Crafting next generation of small molecule anti-parasitic drugs by harnessing comparative structural data At ASTRA Therapeutics, we are redefining parasite drug development by leveraging the specificity of ParabulinsTM. Our mission is clear: to lead the fight against parasitic diseases with precision-engineered solutions.

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Multi-target cell and gene therapies for unmet medical needs. Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapies, based on genetically modified safe lactic acid bacteria, address unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammatory diseases. After successfully completing Phase 1 and Phase 2 clinical studies in Diabetic Foot Ulcer (DFU) with our lead asset AUP-16, we're actively preparing a global DFU Phase 3 study. Other indications will follow In Oncology, we are building on impressive pre-clinical …

193 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Immune Tolerance, Restored. Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.

92 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Addressing "undruggable"​ oncology targets by delivering whole antibodies inside the tumor and metastatic cells. Libera Bio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface, transmembrane or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins. << Fraud Alert for Potential Candidates >> At Libera Bio, your personal information and online safety are our top priorities. • Candidates should apply exclusively through our official webpage at https://www.liberabio.com/contact/ or rrhh@liberabio.com. • If …

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Phialogics state of the art platform transforms native proteins into powerful therapeutics. Phialogics is developing a pipeline of bi-functional, bi-specific and multi-specific molecules to treat autoimmune diseases. Our unique First-in-Class immunomodulatory approach has a proof of concept in several translational in vivo models as well as in patient-derived materials ex vivo.

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Interventional Immuno-Oncology Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their …

75 similar entities Type: Startup Activities: biotech deeptech legaltech Technologies: Synthetic Biology

Chelator-free biologic radiopharma: metal binding engineered directly into antibody and nanobody scaffolds. Machine Bio is a pre-seed radiopharma platform company building chelator-free biologic-format radiopharmaceuticals. We engineer metal-binding architecture directly into antibody and nanobody scaffolds, so the protein itself carries the radiometal. The platform spans β-emitters (Lu-177, Tb-161) and α-emitters (Ac-225, Ra-223), opening therapeutic space synthetic chelator-conjugates can't reach. Our model is partnership-driven: partners bring targeting molecules, and we engineer chelator-free metal binding into them. Protein Synthesis, Protein Purification, Contract Protein Expression, R&D, Startup, Cell-Free Systems, and Supported Lipid Bilayer

64 similar entities Type: Startup Activities: deeptech biotech manufacturing Technologies: Synthetic Biology

Rapid Viral control in a world that needs it Exevir Bio is a biotech company developing efficacious heavy chain-only antibodies to prevent and treat infectious diseases and make a difference in pandemic preparedness. The technology platform of ExeVir uses humanized camelid heavy chain-only antibody fragments (VHH) fused to a human IgG Fc to create new therapeutic compounds. ExeVir is building a strong pipeline of antibody therapies with an initial focus on COVID-19 and dengue. Compared to conventional monoclonal antibodies, the modular VHH building blocks provide a unique combinatory flexibility. In addition, the design of multi-specific constructs is substantially simplified. VHHs …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Protein Sciences (www.proteinsciences.com) is a biotechnology company that specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health by effectively responding to the changing world through the creation of innovative vaccines and biopharmaceuticals. See where Flublok® Influenza vaccine is available at www.flublok.com. We use our proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost. We have developed three main business lines that employ this technology: 1. Proprietary vaccines - we develop and produce the next generation of safer and more effective vaccines 2. GeneXpress® …

133 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

a wholly owned subsidiary of Eli Lilly and Company LimmaTech Biologics AG, a wholly owned subsidiary of Eli Lilly and Company, is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. vaccines, research & development, biotechnology, and antimicrobial resistance

419 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Fighting autoimmune diseases Ahead Therapeutics is a biotech company that uses a proprietary technology to develop a treatment for different auto-immune disorders. Ahead Therapeutics has developed an innovative solution based on the use of liposomes containing autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, thereby interrupting the autoimmune reaction.

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

EXIST Start-up Project Lumatix Biotech is developing a light-controlled affinity matrix for an effective and rapid isolation of antibodies. Our new chromatography technology is intended to significantly advance antibody manufacturing, particular with regard to product quality as well as economic aspects. To achieve these ambitious goals and become a superior alternative to Protein A chromatography, we combine several proprietary technologies. The key innovation here is an affinity matrix with a light-controlled binding mode. By this means, the operator can easily capture antibodies in any user-defined buffer, making acidic elution obsolete. Have a look at our website for further information and …

96 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

435 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Exploiting a new class of tumour specific antigens for cancer therapy A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen. TCR-T cells, Immuno-oncology, Vaccines, Bi-specifics, Splicing, Epigenetics, Oncology, T cell biology, and Antigen presentation

178 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Servier Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers. oncology, immune-evasive, and AXL

215 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Leveraging science and innovation to accelerate the development of next-generation antibody therapeutics. AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, SeqitopeTM and Opti-mAbTM, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs …

144 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Antibody Services from Discovery to Clinical Supply Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client’s projects have advanced to clinical stages, some as far as Phase II. We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of …

137 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Covalab is a French biotechnology company specialized in antibody engineering, founded in 1995. We are expert in the design and development of antibody (polyclonal, monoclonal scFv, FAb, VHH, recombinant antibodies) using antigen or DNA immunization. In addition, we offer purified and labeling antibodies, peptide synthesis for research use, diagnostic and therapeuthic. As a producer, we supply many distributors to sale our innovative and high quality antibodies. Wide range of those products are available in our website. The service activity of CovalAb represents the top of the scientific and technical iceberg which the team at CovalAb has put together. Indeed, the …

106 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

At FairJourney Bio, we specialize in cutting-edge antibody discovery and development, offering end-to-end solutions that fast-track your research. With over a decade of expertise, our innovative technologies and seasoned team have successfully advanced 19 antibodies to clinical stages. Our adaptable partnership model empowers projects of any scale, fostering collaboration and breakthrough innovation. Whether you're in early-stage research or development, we deliver tailored, high-quality antibodies designed to meet your specific needs. Join us in revolutionizing therapeutic discovery and making lasting impacts on global healthcare. Monoclonal antibodies, Antibody humanization, Antibody production, Antibody affinity maturation, Phage display libraries, Mammalian Display, Naïve Libraries, VHH …

193 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

147 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.

177 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention. AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting …

92 similar entities Type: SMB Activities: healthtech biotech deeptech Technologies: Synthetic Biology

The Transcription Infidelity Technology GENCLIS SA is a privately-held French Biotechnology that discovered a unique biological mechanism referred as to Transcription Infidelity (TI). Transcription Infidelity is a newly discovered and patented mechanism that incresases RNA-DNA sequence divergences (RDD). TI can lead to base substitutions, insertions and deletions. The latter cause translational frameshifts that have important consequences in determining protein immunogenicity. Genclis currently focuses on defining the effects of TI proteins translated from gapped RNA on normal and pathological humoral immunity.

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Antibody Magic Oblique Therapeutics AB (publ.) is a Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need with an internal pipeline focusing on pain. The company uses Abiprot®, a proprietary, next-generation antibody platform to identify accessible epitopes for antibody development. biotech, antibody, drug development, and pain

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Swedish clinical stage biopharma company developing disease-modifying treatments against Alzheimer's disease. Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptideTM technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Bioharmony Therapeutics, we are developing nontraditional antimicrobial therapeutics by exploiting millions of years of phage-bacteria evolution. Our focus is on targeting infectious diseases caused by multidrug-resistant (MDR) Gram-negative bacteria. Our primary therapeutic indication is for Acinetobacter baumannii skin and wound infections.

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Autogenous Vaccines Specialists Ridgeway Biologicals are licensed by the VMD (Veterinary Medicines Directorate) to manufacture autogenous vaccine which are veterinary prescription only medicines. Autogenous vaccines are prepared from a pathogen extracted from a host animal or group which is then used to inoculate the rest of the group. We are able to manufacture autogenous vaccine for many farm animals and fish. For more information on autogenous vaccines please contact your veterinary surgeon. autogenous veterinary vaccines

58 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Precision Cancer Immunotherapy At Adularia, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified a novel therapeutic target for immune oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction through activation of tumor-residing macrophages. By leveraging insights from natural metabolic processes, we develop small molecule therapies that enhance the body’s native immune response against cancer. Biotech, Therapeutics, and Immuno-oncology

104 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology